YMYousreya Ali Maklad

Yousreya Ali Maklad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yousreya Ali Maklad has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet‐fed streptozotocin‐treated diabetic rats

    by Noha M. Gamil, Mai A. Abd El Fattah, Maha A. E. Ahmed, Yousreya A. Maklad, Amina A. Gamal el Din, Nihad I. Eid

    Dapagliflozin (DAPA) is used for treating type 2 diabetes, whereas lansoprazole (LPZ) is used as a traditional antiulcer drug. The present study investigated the possible antidiabetic effects of LPZ on fortified diet‐fed streptozotocin (FDF/STZ)‐induced insulin‐resistant diabetic rats. On the basis of the current results, it can be concluded that LPZ could be used as an add‐on drug along with the conventional treatment for T2D as it showed beneficial effects in the current experimental model of insulin resistance.


  • Open Access

    Molecular Docking and Anticonvulsant Activity of Newly Synthesized Quinazoline Derivatives

    by Hatem A. Abuelizz, Rabab El Dib, Mohamed Marzouk, El-Hassane Anouar, Yousreya A. Maklad, Hanan N. Attia, Rashad Al-Salahi

    A new series of quinazoline-4(3H)-ones are evaluated for anticonvulsant activity. After intraperitoneal (ip) injection to albino mice at a dose of 100 mg/kg body weight, synthesized quinazolin-4(3H)-ones (1–24) were examined in the maximal electroshock (MES) induced seizures and subcutaneous pentylenetetrazole (scPTZ) induced seizure models in mice. The Rotarod method was applied to determine the neurotoxicity. Most of the compounds displayed anticonvulsant activity in the scPTZ screen at a dose range of 0.204–0.376 mmol/mL. Out of twenty-four, compounds 8, 13 and 19 proved to be the most active with a remarkable protection (100%) against PTZ induced convulsions and four times more potent activity than ethosuximide. The structure-activity relationship concluded valuable pharmacophoric information, which was confirmed by the molecular docking studies using the target enzyme human carbon anhydrase II (HCA II). The studied quinazoline analogues suggested that the butyl substitution at position 3 has a significant effect on preventing the spread of seizure discharge and on raising the seizure threshold. However, benzyl substitution at position 3 has shown a strong anticonvulsant activity but with less seizure prevention compared to the butyl substitution.


  • Open Access

    Components and antioxidant, anti-inflammatory, anti-ulcer and antinociceptive activities of the endemic species Stachys mialhesi de Noé

    by S. Laggoune, A. Zeghib, A. Kabouche, Z. Kabouche, Y.A. Maklad, F. Leon, I. Brouard, J. Bermejo, C.A. Calliste, J.L. Duroux

    One diterpenoid, horminone 1, two flavonoid glycosides, apigenin-7-O-(6″-E-p-coumaroyl)-β-d-glucopyranoside 2, isoscutellarein-7-O-(6″′-O-acetyl-β-d-allopyranosyl-(1→2)-β-d-glucopyranoside) 3, were isolated from n-butanolic extract of the aerial parts of Stachys mialhesi de Noé (BESM). Their structures were established on the basis of physical and spectroscopic analysis, and by comparison with the literature data. Antioxidant activity of this extract and the compound 3 was evaluated by the use of the Electron Spin Resonance method in order to visualize the inhibition of the DPPH radical. In this study, we also investigated the anti-inflammatory, anti-ulcer and antinociceptive activities of the BESM in experimental animal models at different doses. Our results showed that the BESM showed a strongest antioxidant activity. It decreased acetic acid induced writhing times; inhibited carrageenan-induced hind paw edema. All of these results suggested that the BESM possesses significant antioxidant, antinociceptive and anti-inflammatory activities


  • Synthesis and Anticonvulsant Activity of Substituted‐1,3‐diazaspiro[4.5]decan‐4‐ones

    by Mohamed Nabil Aboul‐Enein, Aida Abdel Sattar El‐Azzouny, Ola Ahmed Saleh, Kamilia Mahmoud Amin, Yousreya Ali Maklad, Rasha Mohamed Hassan

    A series of novel spiroimidazolidinone derivatives6a–dand8a–xwere synthesized and biologically evaluated for their anticonvulsant activity in the maximal electroshock seizure (MES) assay and the subcutaneous pentylenetetrazole (scPTZ) screening test. Compound8wwas the most active derivative in the scPTZ screening test with an ED50value by about 5‐ and 83.6‐fold lower than those of phenobarbital and ethosuximide as reference drugs, respectively. Most of the tested compounds exhibited moderate to weak activity in the MES screen test, except for8awhich displayed 100% protection at 0.09 mmol/kg. Moreover, all the test compounds did not show any minimal motor impairment in the neurotoxicity test.


  • Open Access

    Anticonvulsant Profiles of Certain New 6-Aryl-9-substituted-6,9-diazaspiro-[4.5]decane-8,10-diones and 1-Aryl-4-substituted-1,4-diazaspiro[5.5]undecane-3,5-diones

    by Mohamed N. Aboul-Enein, Aida A. El-Azzouny, Mohamed I. Attia, Yousreya A. Maklad, Mona E. Aboutabl, Fatma Ragab, Walaa H. A. Abd El-Hamid

    Synthesis and anticonvulsant potential of certain new 6-aryl-9-substituted-6,9-diazaspiro[4.5]decane-8,10-diones (6a–l) and 1-aryl-4-substituted-1,4-diazaspiro[5.5] undecane-3,5-diones (6m–x) are reported. The intermediates 1-[(aryl)(cyanomethyl)amino] cycloalkanecarboxamides (3a–f) were prepared via adopting Strecker synthesis on the proper cycloalkanone followed by partial hydrolysis of the obtained nitrile functionality and subsequent N-cyanomethylation. Compounds 3a–f were subjected to complete nitrile hydrolysis to give the respective carboxylic acid derivatives 4a–f which were cyclized under mild conditions to give the spiro compounds 5a–f. Ultimately, compounds 5a–f were alkylated or aralkylated to give the target compounds 6a–i and 6m–u. On the other hand, compounds 6j–l and 6v–x were synthesized from the intermediates 5a–f through alkylation, dehydration and finally tetrazole ring formation. Anticonvulsant screening of the target compounds 6a–x revealed that compound 6g showed an ED50 of 0.0043 mmol/kg in the scPTZ screen, being about 14 and 214 fold more potent than the reference drugs, Phenobarbital (ED50 = 0.06 mmol/kg) and Ethosuximide (ED50 = 0.92 mmol/kg), respectively. Compound 6e exhibited an ED50 of 0.019 mmol/kg, being about 1.8 fold more potent than that of the reference drug, Diphenylhydantoin (ED50 = 0.034 mmol/kg) in the MES screen. Interestingly, all the test compounds 6a–x did not show any minimal motor impairment at the maximum administered dose in the neurotoxicity screen.


  • Open Access

    Anticonvulsant Potential of Certain New (2E)-2-[1-Aryl-3-(1H-imidazol-1-yl)propylidene]-N-(aryl/H)hydrazinecarboxamides

    by Mohamed I. Attia, Mohamed N. Aboul-Enein, Aida A. El-Azzouny, Yousreya A. Maklad, Hazem A. Ghabbour

    Anticonvulsant potential and neurotoxicity of certain new imidazole-containing arylsemicarbazones6a–pare reported. The test compounds6a–pexhibited anticonvulsant activity mainly in the scPTZ screen. Compound6pemerged as the most active surrogate displaying 100% protection at a dose level of 636 μmol/kg in the scPTZ screen without any neurotoxicity. The assigned (E)-configuration of the title compounds6a–pwas confirmedviasingle crystal X-ray structure of compound6g.


  • Design and synthesis of certain substituted cycloalkanecarboxamides structurally related to safinamide with anticonvulsant potential

    by Mohamed N. Aboul-Enein, Aida A. El-Azzouny, Yousreya A. Maklad, Mohamed A. Ismail, Nasser S. M. Ismail, Rasha M. Hassan


  • On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile

    by M. N. Aboul-Enein, A. A. El-Azzouny, O. A. Saleh, Y. A. Maklad

    Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. There has been a considerable interest in the development of many antiepileptic and anticonvulsant agents for controlling epilepsy with fewer side effects and improvement of quality of life. Since the terms antiepileptics /anticonvulsants are used interchangeably, this article reviews their classification according to the chemical structure into: hydantoins, oxazolidinediones, succinimides, barbiturates, amides, benzodiazepines, valproic acid and its derivatives, GABAanalogues, cycloalkanes, semicarbazones, γ butyrolactones (GBLs), imidaquinazolines and pyrrolidine derivatives as well as miscellaneous compounds. In addition, the review discusses the different mechanisms of action of antiepileptic and anticonvulsant agents.


  • Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats

    by Hanan Naeim Attia, Nouf Mohammed Al-Rasheed, Nawal Mohammed Al-Rasheed, Yousreya Ali Maklad, Amany A.E. Ahmed, Sanaa Abdel Baky Kenawy

    Diabetic neuropathy is the most common chronic complication of diabetes. The aim of the present study was to evaluate the protective effects of curcumin against neuropathy in gliclazide-treated diabetic rats. Diabetes was induced by an intraperitoneal injection of streptozotocin (45 mg/kg). Diabetic animals were given gliclazide (10 mg/kg, orally) alone or combined with curcumin (100 mg/kg, orally) or gabapentin (30 mg/kg, intraperitoneally as a positive control). Behavioral responses to thermal (hot plate and tail flick) and mechanical (tail pinch) pain, and some biochemical tests (serum glucose, C-peptide, peroxynitrite, lipid peroxides, and tumor necrosis factor-α) were assessed after 5 consecutive weeks of daily treatment. Combined treatment of curcumin with gliclazide significantly increased hot-plate and tail-flick latencies in comparison with that of the diabetic control group. The threshold of mechanical hyperalgesia was also significantly elevated. Serum glucose and C-peptide levels were significantly increased in the combined treatment compared with the diabetic control group, whereas serum levels of peroxynitrite, lipid peroxide, and tumor necrosis factor-α production were significantly decreased. The data suggest that the combination of curcumin with gliclazide may protect against the development of diabetic neuropathy, with favorable effects with respect to the gliclazide/gabapentin combination.


  • Design and synthesis of novel stiripentol analogues as potential anticonvulsants

    by Mohamed N. Aboul-Enein, Aida A. El-Azzouny, Mohamed I. Attia, Yousreya A. Maklad, Kamilia M. Amin, Mohamed Abdel-Rehim, Mohammed F. El-Behairy